Supplemental Figures S1-S5, Tables S1-S2 from Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

Supplemental Figures S1-S5, Tables S1-S2. This document includes supplemental figures and corresponding legends. Table S1. Differential equations for plasma PK and tumor deposition models. Figure S1. Pharmacokinetic profile of nal-IRI across various tissues. Figure S2. Precision of parameter estimates. Figure S3. Comparing the concentrations of free CPT-11 and total CPT-11 in plasma and tumors. Figure S4. Surrogates for tumor depostion and local activation of nal-IRI. Table S2. Concentrations of CPT-11, SN-38 and CES activity in the panel of xenograft models. Figure S5. In vitro activation of nal-IRI in U937 cell lines.